| Parameter | Details |
|---|---|
| Expression System | E. coli |
| Tag | N-terminal 10xHis |
| Purity | >95% (SDS-PAGE verified) |
| Storage | -20°C (short-term); -80°C (long-term); avoid freeze-thaw cycles |
Recombinant Mouse Tmem158 is widely used to investigate its roles in:
Glioma: Silencing Tmem158 inhibits glioma cell proliferation and migration by suppressing STAT3 activation .
Ovarian Cancer: Overexpression correlates with increased tumor adhesion and invasion via TGF-β1 and BMP4 pathways .
Pancreatic Cancer: Linked to larger tumor size and poor prognosis; knockdown reduces metastasis in vivo .
Acts as a downstream effector of Ras pathway activation, triggering irreversible proliferation arrest .
Used in ELISA kits (e.g., MOEB0832) to quantify Tmem158 levels in biological fluids, with a detection range of 0.156–10 ng/mL and sensitivity of 0.081 ng/mL .
Therapeutic Target: TMEM158 drives epithelial-mesenchymal transition (EMT) in cancers by activating TGF-β and PI3K/AKT pathways .
Prognostic Marker: High expression correlates with poor survival in glioblastoma, ovarian cancer, and laryngeal carcinoma .
While recombinant Tmem158 has advanced mechanistic studies, limitations include:
Lack of crystal structure data for targeted drug design.
Species-specific functional differences between mouse and human orthologs .
Ongoing research focuses on developing TMEM158 inhibitors and exploring its role in modulating immune checkpoints like CTLA4 and LAG3 .
Receptor for brain injury-derived neurotrophic peptide (BINP), a synthetic 13-mer peptide.
UniGene: Mm.8569